Visualization and quantification of disease progression in multiple system atrophy

被引:41
|
作者
Hauser, Till-Karsten
Luft, Andreas
Skalej, Martin
Naegele, Thomas
Kircher, Tilo T. J.
Leube, Dirk T.
Schulz, Joerg B.
机构
[1] Univ Gottingen, Dept Neurodegenerat & Restorat Res, DGF Res Ctr Mol Physiol Brain, Ctr Neuro Med, D-37073 Gottingen, Germany
[2] Univ Tubingen, Ctr Neurol, Dept Gen Neurol, Tubingen, Germany
[3] Univ Tubingen, Hertie Inst Clin Brain Res, Tubingen, Germany
[4] Univ Tubingen, Dept Neuroradiol, Tubingen, Germany
[5] Univ Magdeburg, Dept Neuroradiol, D-39106 Magdeburg, Germany
[6] RWTH Aachen Univ, Dept Psychiat & Psychotherapy, Aachen, Germany
[7] Univ Tubingen, Dept Psychiat & Psychotherapy, Tubingen, Germany
关键词
multiple system atrophy; ataxia; neurodegenerative disorders; parkinsonian syndromes; MR imaging; voxel-based morphometry;
D O I
10.1002/mds.21032
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
To visualize and quantify disease progression in multiple system atrophy (MSA) from cerebellar type (MSA-C), we combined two magnetic resonance imaging (MRI) techniques, voxel-based morphometry (VBM) and 3D-based volumetry. Patients suffering from MSA-C (n = 14) were imaged twice with an interval of 2.0 +/- 0.2 years. We first applied VBM to map brain morphology changes between MSA patients and controls and to identify brain areas that showed a significant amount of atrophy. Using 3D-based volumetry, we confirmed that in MSA-C patients, the brainstem including medulla and pons, vermis and cerebellar hemispheres, caudate nucleus and putamen showed significant atrophy compared with controls. Next, we used 3D-based volumetry to analyze the atrophy rates. Atrophy rates in patients with MSA were significantly different from controls for putamen (- 11.4% +/- 2.6%/year), vermis (-12.3% +/- 2.9%/year), and cerebellar hemispheres (-6.6% +/- 1.1%/year). The results show that 3D-based MRI volumetry is a tool that allows the disease progression of MSA to be followed over a time period of 2 years and suggest that it may serve as a surrogate marker in clinical trials to measure disease progression. (C) 2006 Movement Disorder Society.
引用
收藏
页码:1674 / 1681
页数:8
相关论文
共 50 条
  • [21] Is Multiple System Atrophy an Infectious Disease?
    Wenning, Gregor
    Trojanowski, John Q.
    Kaufmann, Horacio
    Wisniewski, Thomas
    Rocca, Walter A.
    Low, Phillip A.
    [J]. ANNALS OF NEUROLOGY, 2018, 83 (01) : 10 - 12
  • [22] MRI Morphometry in Early Multiple System Atrophy: Correlations with Indices of Disease Burden & Tracking Progression
    Vemuri, Prashanthi
    Castillo, Anna
    Thostenson, Kaely
    Ward, Chadwick
    Reddy, Ashritha
    Gehrking, Tonette
    Gehrking, Jade
    Zeller, Anita
    Jack, Clifford
    Low, Phillip
    Singer, Wolfgang
    [J]. NEUROLOGY, 2019, 92 (15)
  • [23] Serum lipid levels are associated with the prevalence but not with the disease progression of multiple system atrophy in a Chinese population
    Cao, Bei
    Guo, XiaoYan
    Chen, Ke
    Song, Wei
    Huang, Rui
    Wei, Qian-Qian
    Zhao, Bi
    Shang, Hui-Fang
    [J]. NEUROLOGICAL RESEARCH, 2014, 36 (02) : 150 - 156
  • [24] Quantification of pyramidal tract Pathology in multiple system atrophy (MSA)
    Schuepbach, Michael
    Z'Graggen, Werner
    Kaelin-Lang, Alain
    Roesler, Kai M.
    [J]. NEUROLOGY, 2007, 68 (12) : A50 - A50
  • [25] Disease Progression in Multiple System Atrophy: The Value of Clinical Cohorts with Long Follow-Up
    Saulnier, Tiphaine
    Fabbri, Margherita
    Pavy-Le Traon, Anne
    Le Goff, Melanie
    Helmer, Catherine
    Peran, Patrice
    Meissner, Wassilios G.
    Rascol, Olivier
    Foubert-Samier, Alexandra
    Proust-Lima, Cecile
    [J]. MOVEMENT DISORDERS, 2023, 38 (08) : 1567 - 1569
  • [26] Natural History and Disease Progression Biomarkers of Multiple System Atrophy: The ASPIRE-MSA Study
    Del Campo, N.
    Peran, P.
    Payoux, P.
    Rousseau, V.
    Drif, A.
    Catala, H.
    Thalamas, C.
    Tranchant, C.
    Duriff, F.
    Marques, A.
    Azulay, J. P.
    Moreau, C.
    Corvol, J. C.
    Thobois, S.
    Corbille, A. G.
    Frismand, S.
    Patterson, B.
    Foubert-Samier, A.
    Pavy-Letraon, A.
    Fabbri, M.
    Meissner, W.
    Rascol, O.
    [J]. MOVEMENT DISORDERS, 2023, 38 : S68 - S69
  • [27] Disease Progression In Multiple System Atrophy: The Value Of Clinical Cohorts With Long Follow-Up
    Saulnier, T.
    Fabbri, M.
    Pavy-Le Traon, A.
    Le Goff, M.
    Helmer, C.
    Peran, P.
    Meissner, W. G.
    Rascol, O.
    Proust-Lima, C.
    Foubert-Samier, A.
    [J]. MOVEMENT DISORDERS, 2023, 38 : S74 - S74
  • [28] Subcortical nuclei atrophy in multiple sclerosis: depending on disease progression
    Ilves, A.
    Prakhova, L.
    Kataeva, G.
    Totolyan, N.
    Pozdnyakov, A.
    Scoromets, A.
    Stolyarov, I.
    [J]. MULTIPLE SCLEROSIS, 2007, 13 : S177 - S177
  • [29] Progression of cardinal symptoms and MRI findings in multiple system atrophy
    Murata, M.
    Ogawa, M.
    [J]. MOVEMENT DISORDERS, 2010, 25 (07) : S504 - S505
  • [30] Blood NfL Can Track Progression In Multiple System Atrophy
    Chelban, V.
    Perez-Soriano, A.
    Wilke, C.
    Foubert-Samier, A.
    Vijiaratnam, N.
    Guo, T.
    Jabbari, E.
    Senkevich, K.
    Laurens, B.
    Peran, P.
    Rascol, O.
    Schols, L.
    Kobylecki, C.
    Hu, M.
    Rowe, J.
    Foltynie, T.
    Wood, N.
    Heslegrave, A.
    Zetterberg, H.
    Bocchetta, M.
    Rohrer, J.
    Marti, M.
    Synofzik, M.
    Morris, H.
    Meissner, W.
    Houlden, H.
    [J]. MOVEMENT DISORDERS, 2023, 38 : S66 - S67